Progress in Neurotherapeutics and Neuropsychopharmacology
Progress in Neurotherapeutics and Neuropsychopharmacology
Published annually, volumes in this series provide readers with updates of clinical trial results, impacts of trials on guidelines and evidence-based practice, advances in trial methodologies, and the evolution of biomarkers in trials. The series focuses on trials in neurotherapeutics, including disease-modifying and symptomatic agents for neurological diseases, psychopharmacological management of neurologic and psychiatric illnesses, and non-drug treatments. Each paper is authored by a leader in the area of neurotherapeutics and clinical trials, and the series is guided by an editor-in-chief and editorial board with broad experience in drug development and neuropsychopharmacology. Progress in Neurotherapeutics and Neuropsychopharmacology is an essential update of trials in all aspects of the management of neurologic and neuropsychiatric disorders, and will be an invaluable resource for practising neurologists as well as clinical and translational neuroscientists.
- Annual update on clinical trials in neurotherapeutics and psychopharmacology
- Editor, editorial board and contributors are all leading international figures
- Provides the evidence on which to base treatments
- Essential resource for clinicians and neuroscientists
Reviews & endorsements
"Insights provided in this text concerning clinical trials will allow prescribers to feel more confident regarding the medications they prescribe and the quality research on which clinical efficacy has been established. The research is presented in a detailed yet concise and very readable format. The text provides valuable information regarding neuropsychopharmacology research and treatment. It is a well-written and concise read for scientist-practicioners who want an understanding of the clinical trials that support multiple uses of many commonly prescribed agents. It is a must-read for neurologists, psychiatrists, prescribing psychologists, nurse practicioners, and neuroscientists, particularly those interested in clinical issues. Readers who have an interest in the neurobiology of psychiatric issues may be especially interested in this text. This text would be an excellent complement to pharmacology courses because it provides valuable information concerning the drug development process. In addition, this collection of works may facilitate flexible and creative prescribing practices by evaluating agents in populations and for symptoms other than those for which they were initially developed."
Product details
January 2011Adobe eBook Reader
9780511839740
0 pages
0kg
This ISBN is for an eBook version which is distributed on our behalf by a third party.
Table of Contents
- Preface J. L. Cummings
- Introduction to neurotherapeutics and neuropharmacology J. L. Cummings
- 1. Rivastigmine in the treatment of dementia associated with Parkinson's disease: a randomized, double-blind, placebo-controlled study S. Tekin and R. Lane
- 2. Modafinil for the treatment of fatigue in multiple sclerosis B. Stankoff, C. Lubetzki and M. Clanet
- 3. Radiotherapy with concurrent and adjuvant temozolomide: a new standard of care for glioblastoma multiform W. P. Mason, R. O. Mirimanoff and R Stupp
- 4. Treating migraine attacks ASAP: concept and methodological issues N. J. Wiendels and M. D. Ferrari
- 5. Early phase trials of minocycline in amyotropic lateral sclerosis P. H. Gordon, J. Choi, D. H. Moore and R. G. Miller
- 6. Creatine as a potential treatment for amyotrophic lateral sclerosis J. M. Shefner
- 7. AVP-923 as a novel treatment for pseudobulbar affect ALS L. E. Pope
- 8. Liquid fluoxetine vs. placebo for repetitive behaviors in childhood autism E. Hollander, E. Swanson, E. Anagnostou, A. Phillips, W. Chaplin and S. Wasserman
- 9. Testing multiple novel mechanisms for treating schizophrenia in a single trial H. Y. Meltzer
- 10. Selegiline in the treatment of negative symptoms of schizophrenia A. Lin and A. Bodkin
- 11. Analysis of the cognitive enhancing effects of modafinil in schizophrenia D. C. Turner and B. J. Sahakian
- 12. Efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatient with schizophrenia or schizoaffective disorder: results of a double-blind, 6-week study, with a 6-month, double-blind, continuation phase G. M. Simpson, A. Loebel, L. Warrington and R. Yang.
